|Bid||56.00 x 500|
|Ask||57.25 x 400|
|Day's Range||56.25 - 56.92|
|52 Week Range||46.01 - 60.45|
|PE Ratio (TTM)||19.67|
|Dividend & Yield||1.56 (2.76%)|
|1y Target Est||N/A|
In 2Q17, Orencia contributed around 13% of Bristol-Myers Squibb’s net revenues.
In the Phase 3 CheckMate-214 trial, 41.6% patients on Opdivo and Yervoy combination therapy achieved the objective response rate (or ORR) compared to 26.5% patients who were on sunitinib.
In June 2017, Bristol-Myers Squibb presented the clinical trial data of its Phase 1/2 ECHO-204 trial.